BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26200097)

  • 1. Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort.
    Graham RP; Vierkant RA; Tillmans LS; Wang AH; Laird PW; Weisenberger DJ; Lynch CF; French AJ; Slager SL; Raissian Y; Garcia JJ; Kerr SE; Lee HE; Thibodeau SN; Cerhan JR; Limburg PJ; Smyrk TC
    Am J Surg Pathol; 2015 Oct; 39(10):1340-6. PubMed ID: 26200097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.
    Wang LM; Kevans D; Mulcahy H; O'Sullivan J; Fennelly D; Hyland J; O'Donoghue D; Sheahan K
    Am J Surg Pathol; 2009 Jan; 33(1):134-41. PubMed ID: 18971777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.
    O'Connor K; Li-Chang HH; Kalloger SE; Peixoto RD; Webber DL; Owen DA; Driman DK; Kirsch R; Serra S; Scudamore CH; Renouf DJ; Schaeffer DF
    Am J Surg Pathol; 2015 Apr; 39(4):472-8. PubMed ID: 25634751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level.
    Rhee YY; Kim MJ; Bae JM; Koh JM; Cho NY; Juhnn YS; Kim D; Kang GH
    Ann Surg Oncol; 2012 Oct; 19(11):3441-8. PubMed ID: 22618722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer.
    Horcic M; Koelzer VH; Karamitopoulou E; Terracciano L; Puppa G; Zlobec I; Lugli A
    Hum Pathol; 2013 May; 44(5):697-705. PubMed ID: 23159156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor budding in colorectal carcinoma: An institutional interobserver reliability and prognostic study of colorectal adenocarcinoma cases.
    Hacking S; Angert M; Jin C; Kline M; Gupta N; Cho M; Thomas R; Lee L; Chavarria H; Nasim M
    Ann Diagn Pathol; 2019 Dec; 43():151420. PubMed ID: 31731034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left-sided early-onset vs late-onset colorectal carcinoma: histologic, clinical, and molecular differences.
    Pilozzi E; Maresca C; Duranti E; Giustiniani MC; Catalanotto C; Lucarelli M; Cogoni C; Ferri M; Ruco L; Zardo G
    Am J Clin Pathol; 2015 Mar; 143(3):374-84. PubMed ID: 25696795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
    Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
    J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor budding as an indicator of isolated tumor cells in lymph nodes from patients with node-negative colorectal cancer.
    Park SY; Choe G; Lee HS; Jung SY; Park JG; Kim WH
    Dis Colon Rectum; 2005 Feb; 48(2):292-302. PubMed ID: 15616755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.
    Chang YY; Lin JK; Lin TC; Chen WS; Jeng KJ; Yang SH; Wang HS; Lan YT; Lin CC; Liang WY; Chang SC
    Hepatogastroenterology; 2014 Oct; 61(135):1946-53. PubMed ID: 25713893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
    Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
    Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
    Bae JM; Cho NY; Kim TY; Kang GH
    Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis.
    Hu H; Chang DT; Nikiforova MN; Kuan SF; Pai RK
    Am J Surg Pathol; 2013 Nov; 37(11):1660-70. PubMed ID: 23887157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive colorectal carcinoma phenotypes of invasion can be assessed reproducibly and effectively predict poor survival: interobserver study and multivariate survival analysis of a prospectively collected series of 299 patients after potentially curative resections with long-term follow-up.
    Wöhlke M; Schiffmann L; Prall F
    Histopathology; 2011 Nov; 59(5):857-66. PubMed ID: 22092397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
    Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.